Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rosetta Genomics Ltd (ROSG)

Rosetta Genomics Ltd (ROSG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rosetta Genomics Ltd 10 PLAUT STREET SCIENCE PARK REHOVOT L3 76706 ISR

www.rosettagenomics.com P: 972-73-222-0700

Description:

Rosetta Genomics, Ltd. was incorporated under the laws of the State of Israel on March 9, 2000 as Rosetta Genomics Ltd., an Israeli company. It is a development stage company that seeks to develop and commercialize new diagnostic tests based on a recently discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA. It has established a CLIA-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In addition, it is developing body fluid-based diagnostic tests, for other potential indication as part of its longer-term pipeline. The Company is currently focusing on the development and commercialization of new diagnostic tests based on microRNAs. Its industry is highly competitive and subject to rapid and significant technological change.

Key Statistics

Overview:

Market Capitalization, $K 2,550
Shares Outstanding, K 5,930
Annual Sales, $ 9,230 K
Annual Net Income, $ -16,230 K
60-Month Beta 0.49
% of Institutional Shareholders 22.80%

Growth:

1-Year Return -72.96%
3-Year Return -99.03%
5-Year Return -99.02%
5-Year Revenue Growth 9,130.00%
5-Year Earnings Growth -105.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 04/04/18
Earnings Per Share ttm 0.00
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 03/17/17

ROSG Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -175.84%
Debt/Equity N/A
Price/Sales 2.93
Price/Cash Flow N/A
Price/Book 0.94
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar